Eli Lilly and Company

People

Board of Directors

Eli Lilly and Company list their Board of Directors for 2007 as...

• Sidney Taurel - Chairman & CEO
• Winfried Bischoff
• J. Michael Cook
• Martin S Feldstein
• George M C Fisher
• J Erik Fyrwald
• Alfred G Gilman
• Karen N Horn
• John C Lechleiter
• Ellen R Marram
• Franklyn G Prendergast
• Kathi P Seifert

Executive Management

Eli Lilly and Company list their Executive Management for 2007 as comprising...

• Sidney Taurel - Chairman and Chief Executive Officer
• Robert A Armitage - Senior Vice President and General Counsel
• Robert W Armstrong - Vice President, Global External Research and Development, Lilly Research Laboratories
• Alex M Azar II - Senior Vice President, Corporate Affairs and Communications
• Alan Breier - Vice President for Medical and Chief Medical Officer
• Bryce D Carmine - President, Global Product Development
• William W Chin - Vice President, Discovery Research and Clinical Investigation
• Robert A Cole - Vice President, Global Engineering and Environmental Health and Safety
• Deirdre P Connelly - President, Lilly USA
• Newton F Crenshaw - President and General Manager, Lilly Japan
• Andrew M Dahlem - Vice President, Lilly Research Labs Operations
• Frank M Deane - President, Manufacturing
• Alecia A DeCoudreaux - Vice President and General Counsel
• Johanna Carmel Egan - Vice President, Project Management
• Timothy R. Franson - Vice President, Global Regulatory Affairs
• Thomas W Grein - Vice President and Treasurer
• Simon N R Harford - Vice President and Controller
• Michael C Heim - Vice President, Information Technology and Chief Information Officer
• Abbas Hussain- Vice President Europe
• Patrick C James - President, Elanco Animal Health
• Peter J Johnson - Executive Director, Corporate Strategic Planning
• Elizabeth H Klimes - Vice President, Six Sigma
• John C Lechleiter - President and Chief Operating Officer
• Patricia Martin - Vice President, Global Diversity
• Anthony Murphy - Senior Vice President, Human Resources
• Anne Nobles - Vice President, Compliance and Enterprise Risk Management and Chief Compliance Officer
• Steven M Paul - Executive Vice President, Science and Technology, President of Lilly Research Laboratories
• Richard D Pilnik - Group Vice President and Chief Marketing Officer
• Derica W Rice - Senior Vice President and Chief Financial Officer
• Gino Santini - Senior Vice President, Corporate Strategy and Policy
• Sharon L Sullivan - Vice President, Human Resources–Global Compensation and HR Services
• Lorenzo Tallarigo - President, International Operations
• Jacques Tapiero - President, Intercontinental Operations
• Albertus van den Bergh - Vice President, Global Customer Solutions
• Thomas Verhoeven - Vice President for Process and Product Development
• Fionnuala Walsh - Vice President of Quality
• James A Ward - Vice President and Chief Procurement Officer

Patient Groups

Eli Lilly and Company UK report their relationships with Patient Groups in 2006 as follows...

• British Lung Foundation - £20,000, all of which is dedicated to the UK Lung Cancer Coalition.
• Cancer Research UK Scotland - £1,500
• Cancerbackup - £23,000
• Continence Foundation - £11,800 (Lilly in partnership with Boehringer Ingelheim)
• Depression Alliance - $15,000 (Lilly in partnership with Boehringer Ingelheim)
• Diabetes UK - £31,836
• Diabetes UK Scotland - £500
• Hafal - £5,000
• MDF The BiPolar Organisation - £5,000
• Men’s Health Forum - £7,500
• Men’s Health Forum Scotland - £500
• Mesothelioma UK (National Macmillan Mesothelioma Resource Centre) - £20,000
• National Schizophrenia Fellowship (Scotland) - £5,000
• Rethink - £25,000
• Roy Castle Lung Cancer Foundation - £2,000
• Royal National Institute of the Blind Scotland - £4,000
• Sexual Dysfunction Association - £25,000

In 2006, the Lilly Grants Committee has made the following grants:

• Amersham and High Wycombe Branch of the Parkinson´s Disease Society - £400
• Birmingham Parents Group - £200
• British Lung Foundation Scotland - £900
• Centre for Mental Health - £15,000 (in partnership with Boehringer Ingelheim)
• Children´s Holiday Foundation Devon - £250
• Clydebank Asbestos Group - £17,560
• Diabetes Calshot Holiday - £100
• Diabetes West Midlands - £200
• Macmillan Cancer Relief - £2,000
• Mencap - £100
• National Osteoporosis Society (Winchester Support Group) - £100
• National Osteoporosis Society - £250
• Perth and Kinross ADHD Support Group - £1,412
• SeeAbility - £100
• TB Alert - £1,500
• The Tern Veterinary Group - £100
• Winchester Deanery Children´s Society - £150

Affiliations

Eli Lilly list some of their alliances with other organisations as follows. The exact nature and timescales of the alliances are not disclosed.

• Alkermes Inc. - Research & Development alliance to develop inhaled formulations of insulin
• Nicholas Piramal India Limited - Research & Development alliance in the development of several pre-clinical drug candidates
• Structural GenomiX Inc. - Research & Development alliance.
• Amylin Pharmaceuticals Inc. - Commercialization alliance, development and commercialization of diabetes therapies.
• Quintiles Transnational Corp. - Commercialization alliance, promotion & marketing
• Boehringer Ingelheim - Commercialization alliance, promotion & marketing
• Lonza Group - Manufacturing alliance

Particia Martin, Executive Director of alliance management at Eli Lilly reported to Pharmaceutical Executive that Lilly has been partnering for a long time and is involved in hundreds of alliances.

Eli Lilly provided generous support for the Expert Consensus Guideline Series: Treatment of Schizophrenia 1999 an initiative aiming at establishing uniform medication guidelines for schizophrenia. It is reported that this was an initiative 'supported exclusively by 6 pharmaceutical companies: Eli Lilly and Company, Janssen Pharmaceutica Inc., Novartis Pharmaceuticals Corporation, Ortho-McNeil Pharmaceutical, Pfizer Inc. and Zeneca Pharmaceuticals' (now known as AstraZeneca). Michael Hogan and Laurie Flynn were also involved in this initiative.